Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue 2, 2002, Pages 127-134

  Gómez Perez, Francisco J ^a   Fanghänel Salmón, Guillermo ^b   Barbosa, Juan Antonio ^c   Montes Villarreal, Juan ^d   Berry, Rhona A ^e   Warsi, Ghulam ^e   Gould, Errol M ^e,f  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c Centro Medico del Noroeste   (Mexico)

^d HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^e GLAXOSMITHKLINE   (United States)

^f Mail Code 3F0705 ^*  (United States)

Author keywords

Metformin; Rosiglitazone; Type 2 diabetes

Indexed keywords

C PEPTIDE; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ROSIGLITAZONE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYANOTIC HEART DISEASE; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EDEMA; FEMALE; FLATULENCE; FRUCTOSAMINE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEADACHE; HEART MUSCLE ISCHEMIA; HEMOLYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; IMMUNOREACTIVITY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; NAUSEA; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SYNCOPE; TACHYCARDIA; VERTIGO; VOMITING;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; FATTY ACIDS, NONESTERIFIED; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; METFORMIN; MEXICO; MIDDLE AGED; PLACEBOS; SAFETY; THIAZOLES; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 0036244970     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.264     Document Type: Article

References (39)

1. Diabetes in Mexico - A serious and growing problem
2. Tendencia de la mortalidad por cardiopatía isquemica en México de 1950 a 1985
3. Valores de colesterol y cardiopatia isquemica en la República mexicana. Reporte preliminary
4. Association of differing dietary, metabolic, and clinical risk factors with macrovascular complications of diabetes: A prevalence study of 503 Mexican type II diabetic subjects. I
5. Association of differing dietary, metabolic, and clinical risk factors with microvascular complications of diabetes: A prevalence study of 503 Mexican type II diabetics subjects. II
6. The impact of diabetes in public health in Mexico
7. Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio
8. Health status of diabetic Mexican Americans: Results from the Hispanic HANES
9. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: Results from the San Antonio Heart Study
10. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites
11. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
12. [[omega-(Heterocyclylamino) alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents
13. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radio-iodinated ligand for peroxisomal proliferator-activated receptor gamma
14. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
15. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus
16. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes
17. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus
18. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
19. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
20. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients
21. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
22. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
23. United Kingdom Prospective Diabetes Study (UKPDS). Effects of glucose and blood pressure control on complications of type 2 diabetes mellitus
24. Hyperglycemia and microvascular and macrovascular disease in diabetes
25. Long-term glycemic control relates to mortality in type II diabetes
26. Rosiglitazone monotherapy is effective in patients with type 2 diabetes
27. Insulin resistance and coronary heart disease
28. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease patients with Type II diabetes
29. Insulin resistance as an independent risk factor for carotid artery wall intima media thickening in vasospastic angina
30. Epidemiologic aspects of lipid abnormalities
31. Cholesterol and coronary heart disease: Predicting risks by levels and ratios
32. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
33. Central role of the adipocyte in insulin resistance
34. Biguanides: Basic aspects and clinical uses
35. Fatty acids, lipotoxicity and insulin secretion
36. Role of non-esterified fatty acids in the pathogenesis of type 2 diabetes mellitus
37. Nonhypoglycemic effects of thiazolidinediones